+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 120Years
MALE
ID06096870

Phase II Study of Enzalutamide Alone or with PDS01ADC for PET Positive Recurrent Prostate Cancer Without Testosterone Lowering Therapy

Led by National Cancer Institute (NCI) · Updated on 2026-10-16

65

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Prostate cancer can return after initial treatment in many people, and there is no clear best approach for treating this recurrence. This research evaluates the study drug enzalutamide alone and in combination with a second drug called PDS01ADC in men with prostate cancer that has returned and is detected by PET imaging without testosterone lowering therapy. The study aims to determine if combining these drugs increases the duration of prostate-specific antigen PSA suppression compared to enzalutamide alone. Participants will be randomly assigned to one of two groups one receiving enzalutamide alone and the other receiving both enzalutamide and PDS01ADC. Enzalutamide is taken as a daily pill at home, while PDS01ADC is given by injection under the skin once a month. Treatment occurs in cycles of 28 days, with all participants receiving three cycles initially. Some participants may receive an additional three cycles of enzalutamide only if their PSA levels return to baseline. During the study, participants will undergo physical exams, blood and urine tests, and imaging scans of the chest, abdomen, pelvis, and bones to monitor their prostate cancer. Monthly clinic visits lasting up to eight hours will include repeated tests. After treatment, participants have a follow-up visit one month later, then visits every six weeks for up to five years for ongoing monitoring of PSA levels, PET scan changes, immune responses, and safety. The primary outcome measured is the length of PSA suppression over five years.

CONDITIONS

Brief Title

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Research Team

A

Amy R Hankin, P.A.-C

M

Melissa L Abel, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here